. Author manuscript; available in PMC: 2022 Sep 9.

Published in final edited form as: Acta Ophthalmol. 2021 Mar 19;100(1):e91–e99. doi: 10.1111/aos.14852

Table 2.

Retinal outcomes at one year ( ±2 months) postbaseline injection.

		Ranibizumab 0.12 mg (9 infants/18 eyes)	Ranibizumab 0.20 mg (7 infants/14 eyes)	Total (16 infants/32 eyes)
Demarcation line between avascular and vascularized retina visible (ROP stage 1)	No [N, eyes (%)]	16 (100)	12 (100)	28 (100)
	Yes [N, eyes (%)]	–	–	–
	Missing values [N, eyes]	2	2	4
Prominent ridge visible (ROP stage 2)	No [N, eyes (%)]	15 (93.8)	10 (83.3)	25 (89.3)
	Yes [N, eyes (%)]	1 (6.3) (1 clock hour in IIa/III, with inactive proliferations)	2 (16.7) (12 clock hours in IIa; without proliferations)	3 (10.7)
	Missing values [N, eyes]	2	2	4
Late recurrence of ROP^*	No recurrence [N, infants (%)]	9 (100.0)	6 (85.7)	15 (93.8)
	In one eye [N, infants (%)]	–	–	–
	In both eyes [N, infants (%)]	–	1 (14.3)	1 (6.3)
Progression to stage 4 or 5 ROP^†	No progression [N, infants (%)]	9 (100.0)	6 (85.7)	15 (93.8)
	In one eye [N, infants (%)]	–	–	–
	In both eyes [N, infants (%)]	–	1 (14.3)	1 (6.3)

ROP = retinopathy of prematurity.

ROP treatment performed after last visit of the core study.

^†

Between end of core study and year 1 visit.